This is a working overview of 合成肽, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-10-14. Anything still debated is marked as such rather than presented as settled.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Peptide | 28 amino acid residues |
| Molecular weight | Approximately 3108 Da | Depends on acetylation state |
| N-terminal modification | Acetylated | Affects charge and stability |
| Natural source | Fragment of thymosin beta-4 | Cleaved in vivo |
| Sequence length | 28 residues | Synthetic form matches natural |
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
市售的胸腺素α1通常以冻干粉形式提供，溶解后用于注射。其氨基酸组成包括多个酸性残基，因此在中性pH下带负电荷。该肽可溶于水和生理盐水，但在有机溶剂中溶解度有限。储存条件通常为冻干状态下负20摄氏度，溶解后需冷藏并避免反复冻融。常见的同义词包括胸腺肽α1、thymalfasin和Tα1。
胸腺素α1（thymosin alpha 1，Tα1）是一种由28个氨基酸组成的酸性肽，N端被乙酰化，分子量约为3108道尔顿。该肽最早从牛胸腺组织提取物中分离，属于胸腺素组分5的一个成分。其序列在不同哺乳动物中高度保守，提示其具有基本的生物学功能。名称中的“α1”指其在电泳中的迁移位置，并非表示亚型编号。它既存在于胸腺，也存在于脾脏和淋巴结等免疫组织。
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Stability depends on temperature, pH, and the number of freeze-thaw events the sample has experienced. Freeze-dried material is commonly held at -20 °C or colder, while reconstituted liquid is kept cold and used within a short window. Extreme pH and prolonged light exposure can promote deamidation, oxidation, or aggregation, particularly at asparagine and methionine positions. Adsorption to container walls can lower the measured concentration of a dilute solution even when the peptide molecules themselves remain intact.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or chemically modified byproducts. Mass spectrometry confirms the expected molecular mass and can indicate acetylation state or sequence errors. Amino acid analysis and peptide mapping supply complementary sequence-level information, while endotoxin testing is relevant for preparations intended for cell or animal work. Purity figures reported by suppliers refer to the method used and are not directly comparable across laboratories unless conditions are stated.
Lyophilized material is typically treated as a hygroscopic solid that should be brought to room temperature before the container is opened, which limits condensation on the powder. Reconstitution is commonly done with sterile water or a buffered diluent, and gentle mixing is preferred over vigorous agitation to reduce foaming and surface adsorption. Because peptides can bind to plastic and glass, diluents containing a small amount of carrier protein are sometimes used in laboratory work. Working solutions are generally aliquoted and prepared fresh rather than subjected to repeated freezing and thawing.
=== Sequencing === DNA sequencing determines the order of nucleotide bases in a DNA molecule. Synthetic biologists use DNA sequencing in their work in several ways. First, large-scale genome sequencing efforts continue to provide information on naturally occurring organisms. This information provides a rich substrate from which synthetic biologists can construct parts and devices. Second, sequencing can verify that the fabricated system is as intended. Third, fast, cheap, and reliable sequencing can facilitate rapid detection and identification of synthetic systems and organisms.
PfSSM (2008), CBM and CCF (2008) for Plasmodium proteins, which have a different amino acid evolutionary bias due to the low GC content of the genome. Matrices for transmembrane proteins. JTT transmembrane (1994) is the first of the class. Later work include: For alpha-helical transmembrane proteins, PHAT (2000) and SLIM (2001). For beta-barrel transmembrane proteins, bbTM (2008). Matrices for a specific protein family, including GPCRtm (2015) for the transmembrane (mostly helical) regions of GPCRs. Matrices for proteins with a specific role, including Hubsm (2017) for "hub proteins" in protein‐protein interaction networks. Matrices for intrinsically disordered proteins, including DUNMat (2002), MidicMat (2009), Disorder (2010), and EDSSMat (2019).
=== Affinity labeling === Affinity label is a molecule that is similar in structure to a particular substrate for a specific enzyme. It is considered to be a class of irreversible inhibitors. These molecules covalently modify active site residues in order to elucidate the structure of the active site. Using this method, Wilchek collaborated with a team who proved that the binding site of antibodies lies in the Fv portion of the molecule and involves three hypervariable sites, today called the complementarity-determining regions (CDRs).
== Pharmacokinetics == Absorption of orally administered levothyroxine from the gastrointestinal tract ranges from 40 to 80%, with the majority of the drug absorbed from the jejunum and upper ileum. Levothyroxine absorption is increased by fasting and decreased in certain malabsorption syndromes, by certain foods, and with age. Dietary fiber decreases the bioavailability of the drug. Greater than 99% of circulating thyroid hormones are bound to plasma proteins including thyroxine-binding globulin, transthyretin (previously called thyroxine-binding prealbumin), and albumin. Only free hormone is metabolically active. The primary pathway of thyroid hormone metabolism is through sequential deiodination. The liver is the main site of T4 deiodination, and along with the kidneys, are responsible for about 80% of circulating T3. In addition to deiodination, thyroid hormones are also excreted through the kidneys and metabolized through conjugation and glucuronidation and excreted directly into the bile and the gut, where they undergo enterohepatic recirculation. Half-life elimination is 6–7 days for people with normal lab results; 9–10 days for people with hypothyroidism; 3–4 days for people with hyperthyroidism. Thyroid hormones are primarily eliminated by the kidneys (about 80%), with urinary excretion decreasing with age. The remaining 20% of T4 is eliminated in the stool.
==== Cannabis effectively outlawed, prescription drugs ==== With the passage of the Marihuana Tax Act of 1937, federal law reflected state law – by 1936, the non-medical use of cannabis had been banned in every state. That year, the first two arrests for tax non-payment under the act, for possession of a quarter-ounce (7g), and trafficking of four pounds (1.8 kg), resulted in sentences of nearly 18 months and four years respectively. The American Medical Association (AMA) had opposed the tax act on grounds that it unduly affected the medical use of cannabis. The AMA's legislative counsel, a physician, testified that the claims about cannabis addiction, violence and overdoses were not supported by evidence. Scholars have posited that the act was orchestrated by powerful business interests – Andrew Mellon, Randolph Hearst, and the Du Pont family – to head off cheap competition to pulp and timber and plastics from the hemp industry. After the act, cannabis research and medical testing became rare. In 1939, New York City Mayor Fiorello LaGuardia, an opponent of the Marihuana Tax Act, formed the LaGuardia Committee to conduct the first US in-depth study of cannabis use. The report, produced by the New York Academy of Medicine and released in 1944, systematically contradicted government claims, finding that cannabis is not physically addictive, and its use does not lead to using other drugs or to crime. The FBN's Anslinger branded the study "unscientific", denounced all involved, and disrupted other cannabis studies at the time.
Sources: en.wikipedia.org
== Limitations == Different energies in the ion source can cause variations in negative ion formation and make the mass spectra difficult to duplicate. Results shown in the mass spectrum can vary from instrument to instrument. The temperature of the ion source needs to be monitored. An increase in fragment ions occurs at higher temperatures. Lower temperatures will lower the energy of electrons. Set temperatures can vary, but it is important for electron energy to approach thermal levels for resonance electron capture to occur. Pressure of the added enhancement gas needs to be determined. Increasing the pressure will help stabilize the anions and extend the lifetimes of the negative ions. If the pressure is too high, not as many ions can exit the ion source. Analysis should be done using low sample loads for GC-EC-MS. The amount of sample will affect the ion abundance and cause variations in data.
EcPLA, also known as N-ethyl-N-cyclopropyllysergamide or as lysergic acid ethylcyclopropylamide (LAEcP), is a psychedelic drug of the lysergamide family related to lysergic acid diethylamide (LSD). It is an isomer of LSZ and is closely related to other amide-substituted lysergamides like MiPLA. The drug has been encountered as a novel designer drug.
Strontium-90 is a radioactive fission product produced by nuclear reactors used in nuclear power. It is a major component of high-level radioactivity of nuclear waste and spent nuclear fuel. Its 29-year half-life is short enough that its decay heat has been used to power arctic lighthouses, but long enough that it can take hundreds of years to decay to safe levels. Exposure from contaminated water and food may increase the risk of leukemia, bone cancer and primary hyperparathyroidism.
== Orthodox accounts == The first school of interpretation to emerge in the United States was "orthodox". For more than a decade after the end of the World War II, few American historians challenged the official American interpretation of the beginnings of the Cold War. The "orthodox" school places the responsibility for the Cold War on the Soviet Union and its expansion into Eastern Europe. For example, Thomas A. Bailey argued in his 1950 America Faces Russia that the breakdown of postwar peace was the result of Soviet expansionism in the immediate years following World War II. Bailey argued Joseph Stalin violated promises he had made at the Yalta Conference, imposed Soviet-dominated regimes on unwilling Eastern European populations and conspired to spread communism throughout the world. From that view, American officials were forced to respond to Soviet aggression with the Truman Doctrine, plans to contain communist subversion around the world and the Marshall Plan. Another prominent "orthodox" historian was Herbert Feis, who in his works like Churchill, Roosevelt, Stalin and From Trust to Terror: The Onset of the Cold War stated similar views. According to him, Soviet aggression in Eastern Europe in the postwar period was responsible for starting of the Cold War. Apart from this, he also argued that Franklin D. Roosevelt's policies towards Stalin and his "surrender" to Stalin's demands in the Yalta Conference paved the way for Soviet aggression and destabilized balance of power in Europe in Soviet favor.
Sources: en.wikipedia.org
It corresponds to the first 28 amino acids of thymosin beta-4, a larger protein found in many tissues. The fragment is acetylated at its N-terminus and is produced synthetically for research and pharmaceutical use. Synthetic and natural forms share the same sequence.
It is usually described as an immunomodulatory peptide rather than a classical hormone. It does not travel to a single distant organ in the manner of an endocrine hormone. Classification varies across sources, and some texts group it with thymic peptides generally.
The broad outline involves immune cell activation, but the specific molecular steps remain under investigation. Different studies report effects on dendritic cells, T cells, and natural killer cells. No single receptor has been confirmed as the sole mediator.
It is a chain of 28 amino acids, with an acetyl group attached to the first serine residue. The synthetic version replicates this sequence. Its molecular mass is about 3,108 daltons.